Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C28H27ClF5NO |
| Molecular Weight | 523.965 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1(CCN(CCCC(C2=CC=C(F)C=C2)C3=CC=C(F)C=C3)CC1)C4=CC=C(Cl)C(=C4)C(F)(F)F
InChI
InChIKey=MDLAAYDRRZXJIF-UHFFFAOYSA-N
InChI=1S/C28H27ClF5NO/c29-26-12-7-21(18-25(26)28(32,33)34)27(36)13-16-35(17-14-27)15-1-2-24(19-3-8-22(30)9-4-19)20-5-10-23(31)11-6-20/h3-12,18,24,36H,1-2,13-17H2
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/6408670
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6408670
Penfluridol is a highly potent; first generation diphenylbutylpiperidine antipsychotic was developed by Janssen Pharmaceutica in 1968 and is used to treat schizophrenial and similar psychotic disorders. It is, however, like most typical antipsychotics, being increasingly replaced by the atypical antipsychotics. This drug is long-acting dopamine receptor blocker.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2579392
Curator's Comment: # Janssen Pharmaceutica, Beerse, Belgium
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2096905 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6408670 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The position of mefloquine as a 21st century malaria chemoprophylaxis. | 2010-12-09 |
|
| Research on antipsychotics in India. | 2010-01 |
|
| An overview of Indian research in schizophrenia. | 2010-01 |
|
| Antipsychotics and risk of venous thromboembolism: A population-based case-control study. | 2009-08-09 |
|
| Tourette's syndrome: clinical features, pathophysiology, and therapeutic approaches. | 2007 |
|
| Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. | 2006-09 |
|
| Penfluridol for schizophrenia. | 2006-04-19 |
|
| Brief psychotic disorder associated with Sturge-Weber syndrome. | 2005-06 |
|
| Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. | 2005-03 |
|
| An ACTH- and ATP-regulated background K+ channel in adrenocortical cells is TREK-1. | 2002-12-20 |
|
| LC-MS-MS analysis of the neuroleptics clozapine, flupentixol, haloperidol, penfluridol, thioridazine, and zuclopenthixol in hair obtained from psychiatric patients. | 2002-08-09 |
|
| Differential inhibition of T-type calcium channels by neuroleptics. | 2002-01-15 |
|
| Comparative short-term evaluation of penfluridol and trifluoperazine in chronic schizophrenia. | 1988-10-01 |
|
| [Pharmacological studies of antipsychotic drug, penfluridol. 2. General pharmacological properties]. | 1976-07 |
Patents
Sample Use Guides
Initial: 20-60 mg/week. Severe/resistant: ≤250 mg/week.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24528079
Curator's Comment: Growth inhibition of mouse cancer cell lines by penfluridol was determined using the 3- (4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Penfluridol inhibited the proliferation of B16 melanoma (B16/ F10), LL/2 lung carcinoma (LL/2), CT26 colon carcinoma (CT26) and 4T1 breast cancer (4T1) cells in vitro.
Unknown
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C66883
Created by
admin on Mon Mar 31 18:37:17 GMT 2025 , Edited by admin on Mon Mar 31 18:37:17 GMT 2025
|
||
|
WHO-ATC |
N05AG03
Created by
admin on Mon Mar 31 18:37:17 GMT 2025 , Edited by admin on Mon Mar 31 18:37:17 GMT 2025
|
||
|
WHO-VATC |
QN05AG03
Created by
admin on Mon Mar 31 18:37:17 GMT 2025 , Edited by admin on Mon Mar 31 18:37:17 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C90843
Created by
admin on Mon Mar 31 18:37:17 GMT 2025 , Edited by admin on Mon Mar 31 18:37:17 GMT 2025
|
PRIMARY | |||
|
CHEMBL47050
Created by
admin on Mon Mar 31 18:37:17 GMT 2025 , Edited by admin on Mon Mar 31 18:37:17 GMT 2025
|
PRIMARY | |||
|
D010395
Created by
admin on Mon Mar 31 18:37:17 GMT 2025 , Edited by admin on Mon Mar 31 18:37:17 GMT 2025
|
PRIMARY | |||
|
2080
Created by
admin on Mon Mar 31 18:37:17 GMT 2025 , Edited by admin on Mon Mar 31 18:37:17 GMT 2025
|
PRIMARY | |||
|
759179
Created by
admin on Mon Mar 31 18:37:17 GMT 2025 , Edited by admin on Mon Mar 31 18:37:17 GMT 2025
|
PRIMARY | |||
|
SUB09664MIG
Created by
admin on Mon Mar 31 18:37:17 GMT 2025 , Edited by admin on Mon Mar 31 18:37:17 GMT 2025
|
PRIMARY | |||
|
DTXSID5049021
Created by
admin on Mon Mar 31 18:37:17 GMT 2025 , Edited by admin on Mon Mar 31 18:37:17 GMT 2025
|
PRIMARY | |||
|
2919
Created by
admin on Mon Mar 31 18:37:17 GMT 2025 , Edited by admin on Mon Mar 31 18:37:17 GMT 2025
|
PRIMARY | |||
|
100000082499
Created by
admin on Mon Mar 31 18:37:17 GMT 2025 , Edited by admin on Mon Mar 31 18:37:17 GMT 2025
|
PRIMARY | |||
|
248-074-5
Created by
admin on Mon Mar 31 18:37:17 GMT 2025 , Edited by admin on Mon Mar 31 18:37:17 GMT 2025
|
PRIMARY | |||
|
7974
Created by
admin on Mon Mar 31 18:37:17 GMT 2025 , Edited by admin on Mon Mar 31 18:37:17 GMT 2025
|
PRIMARY | RxNorm | ||
|
Penfluridol
Created by
admin on Mon Mar 31 18:37:17 GMT 2025 , Edited by admin on Mon Mar 31 18:37:17 GMT 2025
|
PRIMARY | |||
|
DB13791
Created by
admin on Mon Mar 31 18:37:17 GMT 2025 , Edited by admin on Mon Mar 31 18:37:17 GMT 2025
|
PRIMARY | |||
|
25TLU22Q8H
Created by
admin on Mon Mar 31 18:37:17 GMT 2025 , Edited by admin on Mon Mar 31 18:37:17 GMT 2025
|
PRIMARY | |||
|
m8466
Created by
admin on Mon Mar 31 18:37:17 GMT 2025 , Edited by admin on Mon Mar 31 18:37:17 GMT 2025
|
PRIMARY | Merck Index | ||
|
33630
Created by
admin on Mon Mar 31 18:37:17 GMT 2025 , Edited by admin on Mon Mar 31 18:37:17 GMT 2025
|
PRIMARY | |||
|
26864-56-2
Created by
admin on Mon Mar 31 18:37:17 GMT 2025 , Edited by admin on Mon Mar 31 18:37:17 GMT 2025
|
PRIMARY |
ACTIVE MOIETY